The DOI matches its Crossref record; 434 of the 434 references it cites were found in a registry or an index.
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
Open accessAbstract
The chemokine receptors CXCR1/2 and their ligand CXCL8 are essential for the activation and trafficking of inflammatory mediators as well as tumor progression and metastasis. The CXCL8-CXCR1/2 signaling axis is involved in the pathogenesis of several diseases including chronic obstructive pulmonary diseases (COPD), asthma, cystic fibrosis and cancer. Interaction between CXCL8 secreted by select cancer cells and CXCR1/2 in the tumor microenvironment is critical for cancer progression and metastasis. The CXCL8-CXCR1/2 axis may play an important role in tumor progression and metastasis by regulating cancer stem cell (CSC) proliferation and self-renewal. During the past two decades, several small-molecule CXCR1/2 inhibitors, CXCL8 releasing inhibitors, and neutralizing antibodies against CXCL8 and CXCR1/2 have been reported. As single agents, such inhibitors are expected to be efficacious in various inflammatory diseases. Several preclinical studies suggest that combination of CXCR1/2 inhibitors along with other targeted therapies, chemotherapies, and immunotherapy may be effective in treating select cancers. Currently, several of these inhibitors are in advanced clinical trials for COPD, asthma, and metastatic breast cancer. In this review, we provide a comprehensive analysis of the role of the CXCL8-CXCR1/2 axis and select genes co-expressed in this pathway in disease progression. We also discuss the latest progress in developing small-molecule drugs targeting this pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–434 of 434
A synthetic, non-peptide CXCR2 antagonist blocks MIP-2-induced neutrophil migration in mice
Matzer, S. P., Zombou, J., Sarau, H. M., et al. (2004) · Immunobiology · doi:10.1016/j.imbio.2004.02.009 · Cited by 20
Characterization of the human fMLP receptor in neutrophils and in Xenopus oocytes
Wittmann, S., Fröhlich, D., & Daniels, S. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704592 · Cited by 20
Kyriakakis, E., Cavallari, M., Pfaff, D., Fabbro, D., Mestan, J., Philippova, M., Libero, G. D., Erné, P., & Resink, T. J. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0211097 · Cited by 20
Xu, H., Lu, H., Xu, Z., Luan, L., Li, C., Xu, Y., Dong, K., Zhang, J., Li, X., Li, Y., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00489 · Cited by 20
Interleukin‐8 inhalation directly provokes bronchoconstriction in guinea pigs
Fujimura, M., Myou, S., Nomura, M., et al. (1999) · Allergy · doi:10.1034/j.1398-9995.1999.00891.x · Cited by 19
Yu, Y., Dwyer, M. P., Chao, J., Aki, C., Chao, J., Biju, P., Rindgen, D., Bond, R. W., Mayer-Ezel, R., Jakway, J. P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.024 · Cited by 19
Ijichi, H. (2012) · OncoImmunology · doi:10.4161/onci.19402 · Cited by 19
The Chemokine Receptor, CXCR2, Mediates the Tumorigenic Effects of ELR+ CXC Chemokines
Keane, M. P., Burdick, M. D., Xue, Y., et al. (2004) · CHEST Journal · doi:10.1378/chest.125.5_suppl.133s · Cited by 19
Jiang, Y., Wang, S., Holcomb, J., Trescott, L., Guan, X., Hou, Y., Brunzelle, J. S., Sirinupong, N., Li, C., & Yang, Z. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.028 · Cited by 19
Hill, J. W., & Nemoto, E. M. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0428-z · Cited by 19
Jung, J.-H., Lee, S. J., Kim, J.-H., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2014.0381 · Cited by 18
Pyrimidine-Based Compounds Modulate CXCR2-Mediated Signaling and Receptor Turnover
Ha, H., & Neamati, N. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500180e · Cited by 18
Self-citationNegative regulation of DSS-induced experimental colitis by PILRα
Kishida, K., Kohyama, M., Kurashima, Y., Kogure, Y., Wang, J., Hirayasu, K., Suenaga, T., Kiyono, H., Kunisawa, J., & Arase, H. (2015) · International Immunology · doi:10.1093/intimm/dxv004 · Cited by 18
Biologically active complement (C5)-derived peptides and their relevance to disease
Perez, H. D. (1984) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(84)80012-8 · Cited by 17
Inhibition of IL-8–Mediated MAPK Activation in Human Neutrophils by β1 Integrin Ligands
Xythalis, D., Frewin, M. B., & Gudewicz, P. W. (2002) · Inflammation · doi:10.1023/a:1014836211643 · Cited by 16
CXCL5 is associated with the increased risk of coronary artery disease
Wang, X., Liu, L.-W., Du, X.-M., Gu, R., & Sun, Z.-J. (2015) · Coronary Artery Disease · doi:10.1097/mca.0000000000000292 · Cited by 16
Maeda, D. Y., Peck, A. M., Schuler, A. D., Quinn, M. T., Kirpotina, L. N., Wicomb, W. N., Auten, R. L., Gundla, R., & Zebala, J. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.04.041 · Cited by 16
The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects
Hastrup, N., Khalilieh, S. G., Dale, D. C., Hanson, L. G., Magnusson, P. O., Tzontcheva, A., Tseng, J., Huyck, S. B., Rosenberg, E., & Krogsgaard, K. (2015) · Cytokine · doi:10.1016/j.cyto.2015.01.002 · Cited by 16
Năstase, A., Pâslaru, L., Herlea, V., Ionescu, M., Tomescu, D. R., Bacalbașa, N., Dima, S., & Popescu, I. (2014) · Europe PMC (PubMed Central) · Cited by 16
Schuler, A. D., Engles, C. A., Maeda, D. Y., Quinn, M. T., Kirpotina, L. N., Wicomb, W. N., Mason, S. N., Auten, R. L., & Zebala, J. A. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.090 · Cited by 15
Liu, S., Liu, Y., Wang, H., Ding, Y., Wu, H., Dong, J., Wong, A. S., Chen, S., Li, G., Chan, M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.014 · Cited by 13
Seaton, A., Maxwell, P., Hill, A., Gallagher, R., Pettigrew, J., Wilson, R. H., & Waugh, D. J. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605356 · Cited by 13
New treatments for chronic obstructive pulmonary disease.
Barnes, P. J. (2003) · PubMed · Cited by 13
Ha, H., Bensman, T. J., Ho, H., Beringer, P. M., & Neamati, N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12547 · Cited by 12
Self-citationPancreatic Cancer: Planning Ahead for Metastatic Spread
Stromnes, I. M., & Greenberg, P. D. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.013 · Cited by 12
Backman, S. A., Kollara, A., Haw, R., Stein, L. D., & Brown, T. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097997 · Cited by 10
Spatiotemporal ablation of CXCR2 on oligodendrocyte lineage cells
Liu, L., Spangler, L. C., Prager, B. C., Benson, B. L., Hu, B., Shi, S. X.-Y., Love, A. C., Zhang, C., Yu, M., Cotleur, A. C., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000174 · Cited by 10
Leung, S. J., Rice, P. F. S., & Barton, J. K. (2014) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22309 · Cited by 9
Chen, P., Yi, Z., Zhang, W., Klotman, M. E., & Chen, B. K. (2016) · AIDS · doi:10.1097/qad.0000000000001153 · Cited by 8
New Insights Into ADAMs Regulation of the GRO-α/CXCR2 System: Focus on Sjögren's Syndrome
Sisto, M., & Lisi, S. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.975892 · Cited by 7
Cesarini, S., Spallarossa, A., Ranise, A., Bruno, O., Arduino, N., Bertolotto, M. B., Dallegri, F., Tognolini, M., Gobbetti, T., & Barocelli, E. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.04.006 · Cited by 7
CXCR2-targeted therapy for pancreatic cancer
Dart, A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.67 · Cited by 7
Luo, Q., Ding, Y., Watson, K., Zhang, J., & Fan, G.-H. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011197 · Cited by 6
p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan
Nose, H., Imazeki, F., Ohto, M., & Omata, M. (1993) · Cancer · doi:10.1002/1097-0142(19930715)72:2
Cited by
Tumor angiogenesis: causes, consequences, challenges and opportunities
Lugano, R., Ramachandran, M., & Dimberg, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03351-7 · Cited by 1,986
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Cambier, S., Gouwy, M., & Proost, P. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-00974-6 · Cited by 591
Interleukin-8: An evolving chemokine
Matsushima, K., Yang, D., & Oppenheim, J. J. (2022) · Cytokine · doi:10.1016/j.cyto.2022.155828 · Cited by 520
Motzer, R. J., Robbins, P. B., Powles, T., Albiges, L., Haanen, J. B., Larkin, J., Mu, X. J., Ching, K. A., Uemura, M., Pal, S. K., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1044-8 · Cited by 518
Metadata
- Authors
- Ha, H., Debnath, B., & Neamati, N.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2017
- Volume
- 7
- Issue
- 6
- Pages
- 1543-1588
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2611412386
- Cited by
- 789
- References
- 434
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.